肝病中的蛋白棕化:功能性见解和治疗策略
Ying Wang1, Haoyuan Ma2, Bowen Zhang2
1The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, PR China; Institute of Psychiatry and Neuroscience of Xinxiang Medical University, Xinxiang, Henan, PR China.
Journal of advanced research
|December 28, 2024
概括
蛋白棕化,一个关键的细胞修饰,显著影响肝病的发展和进展. 针对这一过程为新的肝病诊断和治疗提供了潜力.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 肝病学 肝病学是一种肝病学.
背景情况:
- 肝脏疾病,包括脂肪肝和肝细胞癌 (HCC),对全球健康构成重大挑战.
- S-palmitoylation (palmitoylation) 是一种关键的翻译后修饰,涉及棕酸与蛋白质的附着.
- 棕化是细胞功能的组成部分,与肝脏生理学和病理学有关.
研究的目的:
- 为了澄清蛋白质棕化在肝病病理生理学中的作用.
- 评估手掌细胞化作为肝脏疾病诊断和治疗策略的目标.
主要方法:
- 关于蛋白质棕化和肝脏疾病的最新科学文献的综述.
- 分析将棕细胞结合与肝病进展联系起来的机制.
- 对临床应用的向棕细胞结合的评估.
主要成果:
- 蛋白棕化关键调节各种肝病的发展和进展.
- 已经确定了 palmitoylation 影响肝脏病理生理学的特定机制.
- 准棕化通路显示出新型干预措施的前景.
结论:
- 蛋白质棕化是肝脏疾病发病的一个关键因素.
- 调节棕代谢或其调节酶可以产生有效的诊断生物标志物和肝脏疾病的治疗点.
更多相关视频
相关概念视频
Lipids as Anchors
6.0K
In the plasma membrane, the lipids forming the bilayer can also act as an anchor to tether proteins to the membrane. The three main types of lipid anchors found in eukaryotes are – prenyl groups, fatty acyl groups, and glycosylphosphatidylinositol or GPI groups. Prenyl and fatty acyl groups act as anchors on the cytosolic surface of the membrane, whereas GPI anchors proteins on the extracellular side.
The carboxy-terminal of most of the prenylated proteins, such as Ras proteins, contains...
The carboxy-terminal of most of the prenylated proteins, such as Ras proteins, contains...
6.0K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
358
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
358
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Chronic Pancreatitis II: Pathophysiology
30
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
30


